Friday, July 18, 2008

Baxter Q2 - Strong Floseal and Coseal results

Rob Davis said "Sales of regenerative medicine business totaled $109 million and increased 25%, with currency contributing 8 percentage points of growth. This continues to be the result of strong growth of FLOSEAL and COSEAL."
Full transcript HERE

Zymogenetics Q2 results due Aug. 5


Zymogenetics will make Q2 results available August 5th, it will be their first full quarter selling Recothrom. In January, ZymoGenetics launched its first product, Recothrom, a synthetic protein to stop bleeding during surgery, and analysts expect it will generate between $18 million and $23 million in sales this year. Those numbers are below initial estimates but analysts say sales will rise as the product establishes itself in the market.
Zymogenetics have said " The selling process is a long one and could take six months or more to work through with each hospital. We're making progress and expect that work to pay off in the second half of the year."
It will be interesting to see how the figures stack-up.

Omrix to release Q2 results

OMRIX Biopharmaceuticals, Inc. (“OMRIX” or the “Company”) (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced today that it will announce financial results for the second quarter ended June 30, 2008 after the close of the U.S. financial markets on Monday, August 11, 2008. An accompanying conference call to discuss the results will be held the same day at 4:30 pm ET; 1:30 pm PT.
An audio replay of the conference call will be available on the company's website, http://www.omrix.com/, for 30 days. The financial results press release will also be accessible on the company's website at http://www.omrix.com/.